en · de · es · fr · pt
cardarine-notes.peptides3081.com › Topic › Identity And Pharmacological Classification — What the Evidence Shows

Identity And Pharmacological Classification — What the Evidence Shows

By Editorial Desk · published 2025-07-15 · last reviewed 2025-08-19 · Topic

This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.

Identity and Pharmacological Classification

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Cardarine at a glance

PropertyValueNotes
Chemical classPPARδ agonistNot an anabolic steroid.
Common synonymsGW501516, GW-1516Cardarine is an informal name.
AppearanceWhite to off-white powderTypical for research-grade solid.
Solubility classPoorly soluble in water; soluble in some organic solventsSuch as DMSO or ethanol in laboratory settings.
Typical storage temperatureCool, dry, protected from lightSpecific conditions vary by supplier and form.

Background from the literature

Ethanol has been found to enhance GABAA receptor-mediated currents in functional assays. Ethanol has long shown a similarity in its effects to positive allosteric modulators of the GABAA receptor like benzodiazepines, barbiturates, and various general anesthetics. Some of these effects include anxiolytic, anticonvulsant, sedative, and hypnotic effects, cognitive impairment, and motor incoordination. In accordance, it was theorized and widely believed that the primary mechanism of action of ethanol is GABAA receptor positive allosteric modulation. However, other ion channels are involved in its effects as well. Although ethanol exhibits positive allosteric binding properties to GABAA receptors, its effects are limited to pentamers containing the δ-subunit rather than the γ-subunit. Ethanol potentiates extrasynaptic δ subunit-containing GABAA receptors at behaviorally relevant (as low as 3 mM) concentrations, but γ subunit receptors are enhanced only at far higher concentrations (> 100 mM) that are in excess of recreational concentrations (up to 50 mM). GABAA receptors containing the δ-subunit have been shown to be located exterior to the synapse and are involved with tonic inhibition rather than its γ-subunit counterpart, which is involved in phasic inhibition. The δ-subunit has been shown to be able to form the allosteric binding site which makes GABAA receptors containing the δ-subunit more sensitive to ethanol concentrations, even to moderate social ethanol consumption levels (30mM). While it has been shown by Santhakumar et al.

== Functions == Aside from being a proteinogenic amino acid, tyrosine has a special role by virtue of the phenol functionality. Its hydroxy group is able to form the ester linkage, with phosphate in particular. Phosphate groups are transferred to tyrosine residues by way of protein tyrosine kinases. This is one of the post-translational modifications. Phosphorylated tyrosine occurs in proteins that are part of signal transduction processes. Similar functionality is also presented in serine and threonine, whose side chains have a hydroxy group, but are alcohols. Phosphorylation of these three amino acids' moieties (including tyrosine) creates a negative charge on their ends, which is greater than the negative charge of the only negatively charged aspartic and glutamic acids. Phosphorylated proteins keep these same properties—which are useful for more reliable protein-protein interactions—by means of phosphotyrosine, phosphoserine and phosphothreonine. Binding sites for a signalling phosphoprotein may be diverse in their chemical structure. Phosphorylation of the hydroxyl group can change the activity of the target protein, or may form part of a signaling cascade via SH2 domain binding. A tyrosine residue also plays an important role in photosynthesis. In chloroplasts (photosystem II), it acts as an electron donor in the reduction of oxidized chlorophyll. In this process, it loses the hydrogen atom of its phenolic OH-group. This radical is subsequently reduced in the photosystem II by the four core manganese clusters.

Following Geoffrey Howe's resignation speech in November 1990, Heseltine challenged Thatcher for the party leadership, polling well enough to deny her an outright victory on the first ballot. Following Thatcher's subsequent resignation, Heseltine lost to Major on the second ballot, but returned to the Cabinet in his former post of Environment Secretary when Major became prime minister. As a key ally of Major, Heseltine was appointed President of the Board of Trade and Secretary of State for Trade and Industry following the 1992 general election. He supported Major when his leadership was challenged in 1995, and was promoted to Deputy Prime Minister and First Secretary of State. He declined to seek the leadership of the party following Major's 1997 election defeat, and served in Major's shadow cabinet as Deputy Leader of the Opposition, Shadow Chancellor of the Duchy of Lancaster and Shadow Secretary of State for Trade and Industry while the leadership election to succeed him was taking place. Heseltine was created a life peer in 2001 and has remained a vocal advocate of modernisation within the party. He has continued to make political interventions, criticising Brexit and Boris Johnson following the 2016 Brexit referendum result. In 2019, Heseltine had the whip suspended after saying he would vote for the Liberal Democrats, rather than the Conservatives, at the 2019 European Parliament election. Heseltine had the whip restored in July 2024.

Sources: en.wikipedia.org

Related pages on this site

Further detail

=== Present-day === 2025 Military and Security Developments Involving the People's Republic of China (PDF). Arlington, Virginia: United States Department of Defense. 2025. (China Military Power Report, Annual Report to Congress) Chase, Michael S.; Jeffery, Engstrom; Cheung, Tai Ming; Gunness, Kristen A.; Harold, Scott; Puska, Susan; Berkowitz, Samuel K. (2015). China's Incomplete Military Transformation: Assessing the Weaknesses of the People's Liberation Army (PLA). RAND Corporation. ISBN 9780833088307. Fisher, Richard D. (2008). China's Military Modernization: Building for Regional and Global Reach. Praeger Security International. ISBN 9780275994860. Kamphausen, Roy; Lai, David; Scobell, Andrew (2009). Beyond the Strait: PLA Missions Other Than Taiwan. Strategic Studies Institute. ISBN 9781304886385.

== Human proteins containing this domain == EEF1E1; EEF1G; GDAP1; GSTA1; GSTA2; GSTA3; GSTA4; GSTA5; GSTM1; GSTM2; GSTM3; GSTM4; GSTM5; GSTO1; GSTP1; GSTT1; GSTT2; GSTZ1; MARS; HPGDS; PTGDS2; PTGES2; VARS;

=== Routes of exposure === Antineoplastic drugs are usually given through intravenous, intramuscular, intrathecal, or subcutaneous administration. In most cases, before the medication is administered to the patient, it needs to be prepared and handled by several workers. Any worker who is involved in handling, preparing, or administering the drugs, or with cleaning objects that have come into contact with antineoplastic drugs, is potentially exposed to hazardous drugs. Health care workers are exposed to drugs in different circumstances, such as when pharmacists and pharmacy technicians prepare and handle antineoplastic drugs and when nurses and physicians administer the drugs to patients. Additionally, those who are responsible for disposing antineoplastic drugs in health care facilities are also at risk of exposure. Dermal exposure is thought to be the main route of exposure due to the fact that significant amounts of the antineoplastic agents have been found in the gloves worn by healthcare workers who prepare, handle, and administer the agents. Another noteworthy route of exposure is inhalation of the drugs' vapors. Multiple studies have investigated inhalation as a route of exposure, and although air sampling has not shown any dangerous levels, it is still a potential route of exposure. Ingestion by hand to mouth is a route of exposure that is less likely compared to others because of the enforced hygienic standard in the health institutions. However, it is still a potential route, especially in the workplace, outside of a health institute.

Sources: en.wikipedia.org

Background from the literature

However, Smithwick et al.'s study noted that, after further preparation, this irregular surface was simply a layer of sediment with a different color than the rest of the slab. The 'frill' or 'halo' of collagen identified by Feduccia was also determined to be misidentified sediment surrounding one of the specimens. Smithwick et al.'s study concluded by stating that the integument preserved on Sinosauropteryx closely resembled that of birds preserved in the same formation. Purported features of collagen fibers were in fact misidentified shadows formed by scratches or irregular sediment, a misidentification perpetuated by the low quality of early Sinosauropteryx photographs.

The term reticulin was coined in 1892 by M. Siegfried. Today, the term reticulin or reticular fiber is restricted to referring to fibers composed of type III collagen. However, during the pre-molecular era, there was confusion in the use of the term reticulin, which was used to describe two structures:

Monoclonal antibodies that can be used to block pro-inflammatory cytokines Antigen-specific immunotherapy which allows immune cells to specifically target the abnormal cells that cause autoimmune disease Co-stimulatory blockade that works to block the pathway that leads to the autoimmune response Regulatory T cell therapy that utilizes this special type of T cell to suppress the autoimmune response Thymoquinone, a compound found in the flower Nigella sativa, has been studied for potential in treating several autoimmune diseases due to its effects on inflammation.

Osteoblasts can also be stimulated to increase bone mass through increased secretion of osteoid and by inhibiting the ability of osteoclasts to break down osseous tissue. Increased secretion of osteoid is stimulated by the secretion of growth hormone by the pituitary, thyroid hormone and the sex hormones (estrogens and androgens). These hormones also promote increased secretion of osteoprotegerin. Osteoblasts can also be induced to secrete a number of cytokines that promote reabsorption of bone by stimulating osteoclast activity and differentiation from progenitor cells. Vitamin D, parathyroid hormone and stimulation from osteocytes induce osteoblasts to increase secretion of RANK-ligand and interleukin 6, which cytokines then stimulate increased reabsorption of bone by osteoclasts. These same compounds also increase secretion of macrophage colony-stimulating factor by osteoblasts, which promotes the differentiation of progenitor cells into osteoclasts, and decrease secretion of osteoprotegerin.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Is cardarine a steroid?

No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.

Has cardarine been approved for human use?

No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Network